Pfizer's Melanoma Drug Gets New Lease On Phase III Life With Debiopharm Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Analysis of prior Phase III failure helped identify patients who will respond to the cancer immunotherapy tremelimumab.